Serum glycylproline p-nitroanilidase activity in rheumatoid arthritis and systemic lupus erythematosus

doi:10.1016/0009-8981(78)90142-0

Clinica Chimica Acta

Volume 88, Issue 1, 15 August 1978, Pages 15-20

https://doi.org/10.1016/0009-8981(78)90142-0 Get rights and content

Abstract

Glycylproline p-nitroanilidase activity in serum of patients with advanced rheumatoid arthritis or with systemic lupus erythematosus but with normal hepatic function was found to be significantly lower than that of normal adult controls. Decrease of this enzyme's serum activity was more pronounced in systemic lupus erythematosus. A significant inverse correlation was observed between the enzyme activity and the duration of rheumatoid arthritis.

References (20)

H. Oya et al.
Biochim. Biophys. Acta
(1972)
H. Oya et al.
Arch. Oral Biol.
(1972)
M. Hino et al.
Arch. Oral Biol.
(1975)
M. Hino et al.
Clin. Chim. Acta
(1975)
T. Nagatsu et al.
Anal. Biochem.
(1976)
K. Fujita et al.
Clin. Chim. Acta
(1977)
M. Hino et al.
Clin. Chim. Acta
(1976)
V.K. Hopsu-Havu et al.
Histochemie
(1966)
I. Nagatsu et al.
Enzymologia
(1968)
I. Nagatsu et al.
Experientia
(1968)

There are more references available in the full text version of this article.

Cited by (41)

CD26/Dipeptidylpeptidase IV-targeted Therapy of Acute Lung Rejection in Rats
2006, Journal of Heart and Lung Transplantation
CD26 is a T-cell co-stimulator, and interacts with adenosine deaminase, human immunodeficiency virus (HIV) Tat-1 protein and extracellular matrix. It possesses dipeptidylpeptidase IV (DPP IV) catalytic activity, which is linked to its co-stimulatory efficacy. We investigated the effect of specific DPP IV systemic activity inhibition on acute pulmonary rejection.
Rat single-lung transplantation (Tx) was performed (LBNF₁/LEW donor/recipient) in two groups (n = 12). Group I (n = 6) received daily treatment with a Pro-Pro-diphenylphosphonate derivative (AB197), and Group II served as an untreated control. At Day 5 post-Tx, ventilatory parameters, cytotoxicity and mixed lymphocyte reaction were analyzed and staining for ISHLT rejection grade and proliferating cell nuclear antigen (PCNA) was performed.
Treatment with AB192 abrogated acute rejection and preserved pulmonary function up to Day 5 post-Tx for Po₂ (Group II: 24.9 ± 6.9 mm Hg; Group I: 149.5 ± 24.3 mm Hg; p < 0.001), Pco₂ (Group II: 53.3 ± 13.6 mm Hg; Group I: 39.0 ± 9.8 mm Hg; p < 0.05) and peak airway pressure (Group II: 50.7 ± 17.2 mm Hg; Group I: 20.2 ± 10.0 mm Hg; p < 0.01). Controls showed moderate/severe rejection (ISHLT Grade A2 or 3), grafts from inhibited hosts revealed no/mild rejection (Grade A0 to 2: Group II: 2.8 ± 0.3; Group I: 1.25 ± 1.0; p < 0.005). Proliferating cell nuclear antigen (PCNA) staining of rejection-associated cellular infiltrates showed a significant reduction in positivity in perivascular infiltrates (34 ± 11.5%; p < 0.05) and bronchial surface epithelium (31.7 ± 10.6%; p < 0.05) in Group I vs Group II (55.9 ± 8.4% and 57.2 ± 4.5%).
Irreversible enzymatic inhibition of DPP IV has been shown to abrogate acute pulmonary rejection, maintain pulmonary function, and preserve histomorphologic architecture. These results extend earlier findings and illustrate the role of CD26/DPP IV in alloantigen-mediated immune responses.
Applications of dipeptidyl peptidase IV inhibitors in diabetes mellitus
2006, International Journal of Biochemistry and Cell Biology
A number of alternative therapies for type 2 diabetes are currently under development that take advantage of the actions of the incretin hormones glucagon-like peptide-1 and glucose-dependent insulinotropic polypeptide on the pancreatic β-cell. One such approach is based on the inhibition of dipeptidyl peptidase IV (DP IV), the major enzyme responsible for degrading the incretins in vivo. DP IV exhibits characteristics that have allowed the development of specific inhibitors with proven efficacy in improving glucose tolerance in animal models of diabetes and type 2 human diabetics. While enhancement of insulin secretion, resulting from blockade of incretin degradation, has been proposed to be the major mode of inhibitor action, there is also evidence that inhibition of gastric emptying, reduction in glucagon secretion and important effects on β-cell differentiation, mitogenesis and survival, by the incretins and other DP IV-sensitive peptides, can potentially preserve β-cell mass, and improve insulin secretory function and glucose handling in diabetics.
Lowered serum dipeptidyl peptidase IV activity is associated with depressive symptoms and cytokine production in cancer patients receiving interleukin-2-based immunotherapy
2001, Neuropsychopharmacology
There is some evidence that treatment with interleukin-2 (IL-2) and interferon-alpha (IFNα) frequently induces depressive symptoms and activation of the inflammatory response system (IRS). There is evidence that major depression is accompanied by lowered serum activity of dipeptidyl peptidase IV (DPP IV; EC 3.4.14.5), a membrane-bound serine protease which catalyses the cleavage of some cytokines and neuro-active peptides and which modulates T cell activation and the production of cytokines, such as IL-2. This study was carried out to examine the effects of immunochemotherapy with IL-2 and IFNα, alone and together, in cancer patients on serum DPP IV activity in relation to changes in depressive symptoms and the IRS. The Montgomery and Asberg Rating Scale (MADRS), serum DPP IV activity, and the serum IL-6, and IL-2 receptor (IL-2R) concentrations were measured in 26 patients with metastatic cancers before and three and five days after treatment with IL-2 and IFNα, alone or together. Treatment with IL-2 with or without IFNα significantly suppressed serum DPP IV activity. The MADRS scores were significantly elevated by treatment with IL-2 with or without IFNα, but not IFNα alone. The immunochemotherapy-induced decreases in serum DPP IV were significantly and inversely correlated with the increases in the MADRS. Treatment with IL-2 alone or combined with IFNα also elevated serum IL-6 and IL-2R. There were significant and inverse correlations between the immuchemotherapy-induced decreases in serum DPP IV and the elevations in serum IL-6 or IL-2R. In conclusion, treatment with IL-2/IFNα decreases serum DPP IV activity within 3–5 days and the immunochemotherapy-induced decreases in serum DPP IV activity are significantly and inversely related to treatment-induced increases in severity of depression and signs of activation of the IRS.
Decreased dipeptidyl peptidase IV enzyme activity of plasma soluble CD26 and its inverse correlation with HIV-1 RNA in HIV-1 infected individuals
1999, Clinical Immunology
Human plasma contains soluble CD26/dipeptidyl peptidase IV (sCD26/DPPIV) although its physiological significance remains unclear. To determine whether the plasma sCD26 levels have clinical relevance in HIV-1 infected individuals, the concentration and DPPIV enzyme activity of plasma sCD26 were measured. While there is no significant difference between the plasma levels of sCD26 in 90 HIV-1 infected individuals and in 79 uninfected controls, specific DPPIV enzyme activity of sCD26 was significantly decreased in HIV-1 infected individuals (P< 0.0001). Specific DPPIV enzyme activity was correlated with the levels of CD4⁺T cells (r= 0.247;P< 0.02), CD8⁺T cells (r= 0.236;P< 0.03), and adenosine deaminase (r= 0.227;P< 0.05) and had an inverse correlation with HIV-1 RNA (Spearman'sr= 0.474;P= 0.0012). Furthermore, recombinant sCD26 enhanced thein vitroPPD-induced response of lymphocytes from HIV-1 infected individuals with decreased specific DPPIV enzyme activity. These results suggest that the specific DPPIV enzyme activity of plasma sCD26 may contribute to the immunopathogenesis of HIV infection.
Lower serum dipeptidyl peptidase IV activity in treatment resistant major depression: Relationships with immune-inflammatory markers
1997, Psychoneuroendocrinology
Previous research in this laboratory has shown that major depression is accompanied by decreased serum activity of dipeptidyl peptidase IV (DPP IV), a serine protease that cleaves N terminal dipeptides from peptides with penultimate proline or alanine. DPP IV is involved in the metabolism of peptides, T cell activation and proliferation, including the production of cytokines, such as interleukin-1 (IL-1) and IL-2. The aim of this study was to examine (i) serum DPP IV activity in major and treatment resistant depression (TRD) in relation to other established immune and inflammatory markers of that illness, and (ii) the effects of anidepressivetreatment on DPP IV activity. Serum DPP IV activity was significantly lower in major depression and TRD than in normal controls. In normal and major depressed subjects, there were significant and positive relationships between serum DPP IV activity and tital serum protein, serum albumin, zinc, iron and transferrin. In the group of depressed subjects, there were significant and positive relationships between serum DPP IV activity and number of CD4⁺T cells and CD4⁺/CD8⁺ T cell ratio. There were no significant effects of subchronic treatment with antidepressants on serum DPP IV activity. The findings suggest that: (i) lower serum DPP activity may occur in chronic depression, TRD as well as in the acute phase of major depression; (ii) lower serum DPP IV accompanies the ‘chronic’ acute phase response in depression; and (iii) serum DPP IV activity is tightly coupled to increased number of CD4⁺ T cells in depressed subjects, but not in normal controls. Our results do not exclude the possible effects of longer-term treatment with antidepressants on serum DPP-IV activity.
Lower serum prolyl endopeptidase enzyme activity in major depression: Further evidence that peptidases play a role in the pathophysiology of depression
1994, Biological Psychiatry
Prolyl endopeptidase (PEP) is a serine proteinase, which may cleave peptides that are involved in the pathophysiology of major depression, such as arginine vasopressin, β-endorphin, luteinizing hormone-releasing hormone, thyrotropin-releasing hormone, and maybe corticotropin-releasing hormone. PEP may be involved in activation of cell-mediated immunity, autoimmune and inflammatory responses, which repeatedly occur in severe depression. The present study investigates serum PEP activity in 33 normal controls, 16 minor, 14 simple major, and 18 melancholic depressed subjects. Pre-dexamethasone and post-dexamethasone (DST) intact adrenocorticotropic hormone (ACTH) and cortisol values were determined in 33 depressed subjects. Serum PEP activity was siginificantly lower in depressed subjects compared to normal controls and in melancholic depressed subjects compared to minor and simple major depressed subjects. Up to 61.1% of the melancholic patients had serum PEP activities below the mean PEP values of normal controls minus two SDs. In the depressed study group, significant negative correlations between serum PEP activity and severity of illness, post-DST cortisol, and ACTH values were observed. There was a trend toward higher serum PEP activity with increasing age. It is hypothesized that lower serum PEP activity, and lower serum activity of other peptidases, may play a role in the neuroendocrine and immune pathophysiology of major depression.

View all citing articles on Scopus

View full text

Serum glycylproline p-nitroanilidase activity in rheumatoid arthritis and systemic lupus erythematosus

Abstract

Biochim. Biophys. Acta

Arch. Oral Biol.

Arch. Oral Biol.

Clin. Chim. Acta

Anal. Biochem.

Clin. Chim. Acta

Clin. Chim. Acta

Histochemie

Enzymologia

Experientia